TIPRANKS - 2 "STRONG BUY" Penny Stocks that offer massive potential gains, page-6

Morning ALL,

Below is a rehash from two of my previous posts.

I believe it should be regularly pointed out, primarily for the benefit of new/ potential holders that the depth of Dr Triebel's work and ongoing toil is far greater than any single press article or stock price rating can possibly detail.

This incredible man is simply not celebrated enough "YET" and I strongly encourage new holders or those thinking of investing in Immutep to do some background research on this mans amazing work and life story.

BIOGRAPHY:
Frédéric Triebel (born 20 November 1954) is a French immunologist who is best known for his 1990 discovery of the LAG3 immune control mechanism. Triebel worked through the 1990s in a collaboration between Institut Gustave Roussy and Merck Serono to establish LAG-3's mechanism of action in T cells and dendritic cells. In 2001 he founded Immutep SA, a biotech company, to develop the therapeutic potential of LAG3. In 2014 this company was acquired by Prima BioMed and was subsequently renamed IMMUTEP, where Triebel remains Chief Scientific and Medical Officer continuously evolving his incredible discovery.

EARLY LIFE & EDUCATION:
He completed his Doctor of Medicine degree at Poitiers University in 1981 and then a four-year clinical hematology fellowship in Paris hospitals. In 1983, Frédéric Triebel received the Gold Medal of the Paris Medicine University. In parallel, Triebel gained a PhD in Immunology at the University of Paris VI in 1985. His PhD thesis was in the field of immunogenetics, focused on the mechanisms that activate human antigen-specific T-cells.

CAREER:
From 1986 until the late 1990s, Triebel headed the cellular immunology group in the Department of Clinical Biology of the Institut Gustave Roussy. In 1990 he gained a Chair in Molecular Immunogenetics and Biotherapy at the University of Paris XI. Between 1991 and 1996 was director of an INSERM unit (U333). He founded Immutep SA in 2001 in order to develop the clinical potential of LAG3 and stayed with this company through to its acquisition by Prima BioMed in 2014. Triebel remains Chief Scientific and Medical Officer of Immutep.

IMO.
The resilience and belief of Dr Triebel to remain focused for over 30 years and deliver this science to patients that need help is a champions effort. We should all be grateful to Dr Triebel and vigorously applaud his incredible work, what a enormous sacrifice & contribution he has made to medical science and the good of humanity.

MUSINGS?
In 1928 penicillin, the first true antibiotic, was discovered by Alexander Fleming, Professor of Bacteriology at St. Mary's Hospital in London.

March 1944.
Penicillin Standard and Antibiotic Certification.

By 1944 the subcommittee on Scope approved penicillin standard for admission to the USP, and in 1945, the FDCA was amended to require FDA certification of penicillin. Subsequent amendments extended this certification to encompass all antibiotics.

POTENTIALLY & IMHO:
Dr Triebel's LAG-3 discovery may prove just as significant as Alexander Fleming's penicillin discovery in 1928 and hence become the new standard of care in many treatment settings.

Good luck to ALL holders.
DYOR
IMHO